FDA Accepts Daraxonrasib for Pancreatic Cancer

Company Revolution Medicines Event Type Regulatory Filing Acceptance (FDA NDA) Modality Small-Molecule RAS(ON) Inhibitor (Multi-Selective) Asset Daraxonrasib Target RAS (Multi-Variant, GTP-Bound) Disease Area Metastatic Pancreatic Ductal Adenocarcinoma Summary The FDA accepted Revolution Medicines’ NDA for oral daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. The…